

J-M Michot

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8847899/j-m-michot-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

173
papers

7,047
citations

40
h-index

82
g-index

220
ext. papers

8,940
ext. citations

4.3
avg, IF

5.74
L-index

#	Paper	IF	Citations
173	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016 , 54, 139-148	7.5	1239
172	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Annals of Oncology</i> , 2016 , 27, 559-74	10.3	548
171	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3733-3739	2.2	486
170	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. <i>Lancet Oncology, The</i> , 2018 , 19, 649-659	21.7	307
169	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020 , 31, 961-964	10.3	222
168	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018 , 68, 1181-1190	13.4	222
167	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2017 , 130, 267-270	2.2	201
166	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	192
165	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014 , 124, 1119-26	2.2	163
164	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1310-1317	13.4	161
163	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018 , 91, 21-29	7.5	158
162	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017 , 82, 34-44	7.5	110
161	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology, the</i> , 2019 , 6, e48-e57	14.6	109
160	PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). <i>Blood</i> , 2014 , 124, 290-290	2.2	95
159	Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. <i>Blood</i> , 2012 , 119, 2228-33	2.2	80
158	F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 15-24	8.9	78
157	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017 , 84, 212-218	7.5	78

156	1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy. <i>Annals of Oncology</i> , 2020 , 31, S1000-S1001	10.3	78
155	1617P Sustained cancer clinical trial activity during the COVID-19 pandemic. <i>Annals of Oncology</i> , 2021 , 32, S1151	10.3	78
154	1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy. <i>Annals of Oncology</i> , 2021 , 32, S1159	10.3	78
153	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. <i>European Journal of Cancer</i> , 2018 , 96, 91-104	7.5	73
152	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. <i>American Journal of Hematology</i> , 2015 , 90, 197-203	7.1	72
151	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017 , 28, 2860-2865	10.3	71
150	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017 , 6, S8-S20	4.4	67
149	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019 , 25, 946-956	12.9	67
148	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019 , 12, 81-88	4.5	61
147	A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. <i>Haematologica</i> , 2013 , 98, 881-7	6.6	58
146	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. <i>Nature Cancer</i> , 2020 , 1, 965-975	15.4	58
145	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 7331-7339	12.9	55
144	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 574-83	2.2	54
143	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. <i>European Journal of Cancer</i> , 2019 , 122, 72-90	7.5	53
142	Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013 , 106, 1017-22	2.7	53
141	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015 , 14, 680-5	13.6	49
140	A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). <i>American Journal of Hematology</i> , 2017 , 92, 23-27	7.1	48
139	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016 , 54, 172-174	7.5	47

138	Immuno-hematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. <i>Transfusion</i> , 2015 , 55, 357-63	2.9	45
137	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study 2019 , 7, 337		45
136	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. <i>American Journal of Ophthalmology</i> , 2019 , 202, 109-117	4.9	42
135	Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. <i>European Journal of Cancer</i> , 2016 , 66, 91-4	7.5	42
134	Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. <i>European Journal of Cancer</i> , 2017 , 81, 135-137	7.5	40
133	Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. <i>European Journal of Cancer</i> , 2018 , 101, 160-164	7.5	39
132	Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. <i>Arthritis Care and Research</i> , 2013 , 65, 1504-14	4.7	39
131	Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 468-470	2.4	38
130	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021 , 12, 258	9.8	37
129	From hepatitis C virus infection to B-cell lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 92-100	10.3	34
128	Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. <i>Blood</i> , 2015 , 126, 473-473	2.2	34
127	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e67	2.4	31
126	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2017 , 23, 6411-6420	12.9	27
125	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2018 , 91, 136-144	7.5	26
124	Immune-related bone marrow failure following anti-PD1 therapy. <i>European Journal of Cancer</i> , 2017 , 80, 1-4	7.5	25
123	Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2018-2024	8.8	24
122	Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. <i>Open Forum Infectious Diseases</i> , 2014 , 1, ofu074	1	24
121	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015 , 51, 2386-95	7.5	23

120	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. <i>Clinical Cancer Research</i> , 2020 , 26, 3145-3153	12.9	23
119	Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study. <i>Blood</i> , 2016 , 128, 1108-1108	2.2	23
118	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020 , 2, 100170	10.3	23
117	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. <i>Blood Advances</i> , 2020 , 4, 2617-2622	7.8	22
116	Severe chronic primary neutropenia in adults: report on a series of 108 patients. <i>Blood</i> , 2015 , 126, 1643-50		22
115	Successful outcome of a corticoid-dependent henoch-schleien purpura adult with rituximab. <i>Case Reports in Medicine</i> , 2014 , 2014, 619218	0.7	22
114	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. <i>PLoS ONE</i> , 2016 , 11, e0162965	3.7	22
113	Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. <i>European Journal of Cancer</i> , 2020 , 129, 71-79	7.5	21
112	Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication. <i>Journal of Immunotherapy</i> , 2018 , 41, 84-85	5	20
111	PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment. <i>Blood</i> , 2015 , 126, 584-584	2.2	19
110	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients 2020 , 8,		19
109	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020 , 130, 39-50	7.5	17
108	Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2017 , 85, 67-77	7.5	16
107	Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019 , 134, 4079-4079	2.2	16
106	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016 , 11, e0156384	3.7	16
105	Psychosis, paraplegia and coma revealing methylenetetrahydrofolate reductase deficiency in a 56-year-old woman. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008 , 79, 963-4	5.5	15
104	A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). <i>Blood</i> , 2016 , 128, 4203-4203	2.2	15
103	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020 , 9, 2643-2652	4.8	14

102	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	14
101	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. <i>European Journal of Cancer</i> , 2018 , 95, 68-74	7.5	13
100	Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2015 , 126, 3986-3986	2.2	13
99	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. <i>British Journal of Haematology</i> , 2020 , 189, 244-256	4.5	12
98	Adenosine deaminase is a useful biomarker to diagnose pleural tuberculosis in low to medium prevalence settings. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016 , 84, 215-20	2.9	12
97	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology</i> , 2020 , 7, e649-e659	14.6	12
96	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018 , 92, 1-10	7.5	11
95	Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. <i>American Journal of Hematology</i> , 2015 , 90, E131-2	7.1	11
94	A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2580-2587	10.9	11
93	Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. <i>Annals of Oncology</i> , 2021 , 32, 1445-1447	10.3	11
92	Infectious complications in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020 , 141, 137-142	7.5	10
91	Severe gastro-intestinal angiodysplasia in context of Heyde's syndrome durably cured after aortic valve replacement. <i>Presse Medicale</i> , 2012 , 41, 763-6	2.2	10
90	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. <i>European Journal of Cancer</i> , 2020 , 141, 239-251	7.5	10
89	Burkitt and Burkitt-Like Lymphomas: a Systematic Review. <i>Current Oncology Reports</i> , 2020 , 22, 33	6.3	9
88	Ibrutinib-Induced Neutrophilic Dermatitis. <i>American Journal of Dermatopathology</i> , 2018 , 40, 198-200	0.9	9
87	Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2018 , 29, 518-520	10.3	9
86	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015 , 126, 4263-4263	2.2	9
85	Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	9

84	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. <i>British Journal of Haematology</i> , 2020 , 189, 985-992	4.5	8
83	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <i>Annals of Intensive Care</i> , 2020 , 10, 143	8.9	8
82	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 137, 117-126	7.5	8
81	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021 , 11, 1336-1344	24.4	8
80	Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 8-20.e3	2	8
79	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018 , 9, 9741-9750	3.3	7
78	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 221-232	7.4	7
77	Repeated courses of low-dose 200Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. <i>Cancer Medicine</i> , 2020 , 9, 3725-3732	4.8	6
76	Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial. <i>Blood</i> , 2016 , 128, 619-619	2.2	6
75	Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. <i>European Journal of Cancer</i> , 2017 , 75, 308-309	7.5	5
74	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. <i>Immunotherapy</i> , 2019 , 11, 591-598	3.8	5
73	Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery. <i>Ophthalmology</i> , 2020 , 127, 1626	7.3	5
72	Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8006-8006	2.2	5
71	Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2021 , 138, 2494-2494 ^{2.2}	2.2	5
70	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2021 ,	7.5	5
69	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. <i>British Journal of Cancer</i> , 2018 , 119, 937-939	8.7	5
68	Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. <i>European Journal of Cancer</i> , 2018 , 98, 17-22	7.5	5
67	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021 , 158, 208-216	7.5	5

66	Severe COVID-19 in patients with hematological cancers presenting with viremia. <i>Annals of Oncology</i> , 2021 , 32, 1297-1300	10.3	5
65	Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 566-9	14.3	4
64	Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 449-449	2.2	4
63	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. <i>Blood</i> , 2018 , 132, 1627-1627	2.2	4
62	Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. <i>Annals of Oncology</i> , 2018 , 29, viii405	10.3	4
61	Clinical efficacy of HER3 partnersInhibitors in ERBB3 mutated cancer patients. <i>Annals of Oncology</i> , 2016 , 27, vi38	10.3	3
60	BRAF V600E Targetable Mutation in Relapsed/Refractory Multiple Myeloma (R/R MM) Patients: A High Incidence in R/R MM Detected Using Cell Sorting Screening. <i>Blood</i> , 2016 , 128, 5638-5638	2.2	3
59	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. <i>Cancer</i> , 2021 ,	6.4	3
58	Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. <i>Lancet, The</i> , 2021 , 397, 855-857	4.0	3
57	Updates in the Treatment of Peripheral T-Cell Lymphomas. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 577-591	3	3
56	Haemophagocytic histiocyte in a peripheral blood film. <i>British Journal of Haematology</i> , 2014 , 165, 163	4.5	2
55	An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 2015 , 3,		2
54	Large granular lymphocyte leukemia and lymphomatoid granulomatosis in the same patient: fortuitous association?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 432-4	1.9	2
53	Abstract CT029: The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors 2016 ,		2
52	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 41-42	2.2	2
51	BEAM or BeEAM High-Dose Chemotherapy Followed By ASCT: A Single Center Comparative Analysis of Toxicity. <i>Blood</i> , 2016 , 128, 4648-4648	2.2	2
50	Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE Antibody ARGX-110.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7556-7556	2.2	2
49	High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-HodgkinS lymphoma, a phase II result. <i>European Journal of Haematology</i> , 2020 , 104, 281-290	3.8	2

48	THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) 2019 ,		2
47	Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, e373-e380	2	2
46	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. <i>Clinical Rheumatology</i> , 2021 , 40, 1933-1940	3.9	2
45	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. <i>European Journal of Cancer</i> , 2021 , 156, 46-59	7.5	2
44	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021 , 3, fcab220	4.5	2
43	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021 , 157, 282-290	7.5	2
42	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018 , 36, 62-74	4.3	1
41	Distinct efficacy of pegylated-interferon α and β during treatment of essential thrombocythemia. <i>International Journal of Hematology</i> , 2013 , 97, 438-9	2.3	1
40	Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. <i>Anti-Cancer Drugs</i> , 2017 , 28, 540-545	2.4	1
39	Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study. <i>Blood</i> , 2018 , 132, 4191-4191	2.2	1
38	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. <i>Blood</i> , 2015 , 126, 1464-1464	2.2	1
37	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimmune Hemolytic Anemia in Adults. <i>Blood</i> , 2015 , 126, 3338-3338	2.2	1
36	A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 4199-4199	2.2	1
35	Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1422-1422	2.2	1
34	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin α 4 therapy. <i>European Journal of Cancer</i> , 2021 , 145, 230-233	7.5	1
33	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019 , 70, 566-567	13.4	1
32	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018 , 69, 1397-1398	13.4	1
31	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.. <i>European Journal of Cancer</i> , 2022 , 167, 42-53	7.5	1

30	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018 , 69, 550-551	13.4	○
29	Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT. <i>Blood</i> , 2018 , 132, 4226-4226	2.2	○
28	Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study. <i>Blood</i> , 2021 , 138, 3574-3574	2.2	○
27	Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials. <i>Blood</i> , 2021 , 138, 3763-3763	2.2	○
26	Evaluation of PFS ratio in patients with cancer enrolled in early-phase clinical trials: A single center, retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14025-e14025	2.2	○
25	Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study. <i>European Journal of Cancer</i> , 2021 , 148, 211-214	7.5	○
24	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study. <i>American Journal of Hematology</i> , 2021 , 96, E376-E379	7.1	○
23	Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy. <i>European Journal of Haematology</i> , 2021 , 106, 574-583	3.8	○
22	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. <i>Annals of Oncology</i> , 2021 , 32, 936-937	10.3	○
21	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021 , 39, 1039-1041	24.3	○
20	Late recurrent testicular seminoma: histological evidence is required. <i>Oncology Research and Treatment</i> , 2015 , 38, 286-8	2.8	
19	Letter responds to the comment in Immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty? <i>European Journal of Cancer</i> , 2020 , 134, 60-61	7.5	
18	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018 , 69, 978-979	13.4	
17	High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 10-11	2.2	
16	Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?. <i>Blood</i> , 2020 , 136, 18-19	2.2	
15	Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon. <i>EXCLI Journal</i> , 2021 , 20, 819-827	2.4	
14	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. <i>Blood</i> , 2018 , 132, 2412-2412	2.2	
13	Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials. <i>Blood</i> , 2018 , 132, 2992-2992	2.2	

- 12 Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma. *Blood*, **2018**, 132, 2001-2001 2.2
- 11 Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Blood*, **2018**, 132, 4110-4110 2.2
- 10 Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas. *Blood*, **2019**, 134, 1496-1496 2.2
- 9 A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience. *Blood*, **2014**, 124, 1759-1759 2.2
- 8 Prognostic Factors and Outcome of Patients with Hematological Malignancies in Phase I Trials: The Gustave Roussy Scoring System. *Blood*, **2014**, 124, 3504-3504 2.2
- 7 Concurrent Radiation and ESHAP Regimen in Localized Extranodal NK/T-Cell Lymphoma Nasal Type, Phase II French Study. *Blood*, **2014**, 124, 1707-1707 2.2
- 6 Repetitive Low-Dose Radiation Therapies As an Alternative Option for Indolent Non-Hodgkin Lymphoma. *Blood*, **2016**, 128, 1784-1784 2.2
- 5 Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. *Blood*, **2013**, 122, 3005-3005 2.2
- 4 47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. *Annals of Oncology*, **2020**, 31, S1435 10.3
- 3 Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?. *Human Vaccines and Immunotherapeutics*, **2021**, 17, 3502-3510 4.4
- 2 Local treatment for scleritis secondary to Wiskott-Aldrich syndrome. *Journal Francais D'Ophtalmologie*, **2016**, 39, e63-4 0.8
- 1 Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. *Hematologie*, **2018**, 24, 183-193 0